Related references
Note: Only part of the references are listed.Multivariate analysis of prognostic factors in patients with nodular melanoma
L. Susok et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)
Five-year survival in patients with nodular and superficial spreading melanomas in the US population
Blair S. Allais et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
Clinical Suspicion Sensitivity of Nodular and Superficial Spreading Melanoma
Trude E. Robsahm et al.
ACTA DERMATO-VENEREOLOGICA (2021)
Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial
Xinan Sheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy (vol 17, 245, 2019)
Longwen Xu et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients
Bixia Tang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Multifactorial Analysis of Prognostic Factors and Survival Rates Among 706 Mucosal Melanoma Patients
ChuanLiang Cui et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
The existence of early stage oral mucosal melanoma: A 10-year retrospective analysis of 170 patients in a single institute
Yunteng Wu et al.
ORAL ONCOLOGY (2018)
The safety of anti PD-1 therapeutics for the treatment of melanoma
Egle Ramelyte et al.
EXPERT OPINION ON DRUG SAFETY (2017)
Ki67 Proliferation Index as a Histopathological Predictive and Prognostic Parameter of Oral Mucosal Melanoma in Patients without Distant Metastases
Xuhui Ma et al.
JOURNAL OF CANCER (2017)
Clinical investigation of 38 cases of oral mucosal melanoma: A multicentre retrospective analysis in Japan
Shin-ichi Yamada et al.
AUSTRALASIAN JOURNAL OF DERMATOLOGY (2017)
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
Jeffrey E. Gershenwald et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Optimal multidisciplinary treatment of oral cavity mucosal melanoma: outcome analysis in a case series
Francesco Perri et al.
ANTI-CANCER DRUGS (2017)
Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials
Seongseok Yun et al.
CANCER MEDICINE (2016)
Interferon-alpha-2b as an adjuvant therapy prolongs survival of patients with previously resected oral muscosal melanoma
R. Wang et al.
GENETICS AND MOLECULAR RESEARCH (2015)
Southwest Oncology Group S0008: A Phase III Trial of High-Dose Interferon Alfa-2b Versus Cisplatin, Vinblastine, and Dacarbazine, Plus Interleukin-2 and Interferon in Patients With High-Risk Melanoma-An Intergroup Study of Cancer and Leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group
Lawrence E. Flaherty et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Neck dissection for oral mucosal melanoma: Caution of nodular lesion
Yunteng Wu et al.
ORAL ONCOLOGY (2014)
Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma
Bin Lian et al.
CLINICAL CANCER RESEARCH (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of Intergroup trial E1694/S9512/C509801
JM Kirkwood et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
